Results
In our previous reports, we showed that intestinal dysbiosis mediates
the development of experimental AIP by activating pDCs, which have the
ability to produce large amounts of IFN-α and IL-33 [6, 14, 16, 19,
20]. This study aimed to clarify alterations in gut microbiota that
have been poorly defined in type 1 AIP patients.